retatrutide phase 2 nejm 2023 weight loss percent 48 weeks Tirzepatide as Compared with Semaglutide for the Treatment of Obesity Reta Weight Loss: Phase 3
Description
Additional benefits are expected from double and triple agonists, but specific human clinical trials are needed
Table 1 Clinical characteristics of the 44 obese stone formers followed longitudinally The GLP-based therapies used during the weight loss intervention included semaglutide (86%), tirzepatide (48%), liraglutide (21%), and dulaglutide (14%), with patients switching between these agents on the basis of insurance coverage and/or medication availability
Follow all directions on your prescription label and read all medication guides or instruction sheets
Liraglutide was administered to mice after suppression of the gut microbiota by antibiotics
(2015) 3:e00155
